You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ketanserin

Showing 1 - 17 of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Trial (LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg))

Not yet recruiting
  • Healthy
  • LSD (150 µg) + ketanserin (40 mg)
  • +4 more
  • (no location specified)
Jul 27, 2023

Healthy Trial in Basel (Lysergic Acid Diethylamide, Ketanserin Placebo, Ketanserin)

Completed
  • Healthy
  • Lysergic Acid Diethylamide
  • +2 more
  • Basel, Switzerland
    Clinical Pharmacology & Toxicology, University Hospital Basel
Oct 20, 2021

Basic Science Trial in Copenhagen (Psilocybine, Ketanserin)

Recruiting
  • Basic Science
  • Copenhagen, Denmark
    Neurobiology Research Unit, Rigshospitalet
Aug 11, 2022

Healthy Trial in Basel (Placebo, Mescaline 100mg, Mescaline 200mg)

Recruiting
  • Healthy
  • Placebo
  • +5 more
  • Basel, BS, Switzerland
    University Hospital Basel, Clinical Trial Unit
Aug 17, 2021

Depression, Serotonin Deficiency Trial in Kelowna (Pharmacological agent: Citalopram, Placebo)

Not yet recruiting
  • Depression
  • Serotonin Deficiency
  • Pharmacological agent: Citalopram
  • Placebo
  • Kelowna, British Columbia, Canada
    University of British Columbia, Okanagan Campus
Jul 19, 2023

Postoperative Shivering, Cesarean Delivery Trial in Peshawar (Dexmedetomidine Hydrochloride, Normal Saline)

Recruiting
  • Postoperative Shivering
  • Cesarean Delivery
  • Dexmedetomidine Hydrochloride
  • Normal Saline
  • Peshawar, Khyber Pakhtunkhwa, Pakistan
    Rehman Medical Institute
May 5, 2022

Critical Illness Trial (Ketanserin, Placebo)

Unknown status
  • Critical Illness
  • Ketanserin
  • Placebo
  • (no location specified)
Aug 22, 2018

Healthy Trial in Basel (LSD, Placebo)

Completed
  • Healthy
  • Basel, Switzerland
    University Hospital
Aug 26, 2019

Tourette Syndrome, Tardive Dyskinesia Trial in Houston (Pimavanserin)

Completed
  • Tourette Syndrome
  • Tardive Dyskinesia
  • Houston, Texas
    Baylor College of Medicine
Mar 10, 2021

Rivaroxaban for Intermittent Claudication and Exercise Tolerance

Not yet recruiting
  • Peripheral Arterial Disease
  • (no location specified)
Mar 8, 2021

Parkinson Disease, Impulse Control Disorders Trial in Bron (Positron Emission Tomography using [11

Unknown status
  • Parkinson Disease
  • Impulse Control Disorders
  • Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)
  • Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
  • Bron, France
    Hospices Civils de Lyon
Apr 7, 2020

Acute Renal Failure Trial in Gdansk (fenoldopam (Corlopam), , ketanserin (Sufrexal))

Terminated
  • Acute Renal Failure
  • fenoldopam (Corlopam)
  • +2 more
  • Gdańsk, Poland
    Department of Cardiac Anesthesiology, Medical University of Gdań
Nov 14, 2016

Diabetic Foot Ulcer Trial in Guadalajara, Zapopan (Pirfenidone with MODD, Ketanserin)

Completed
  • Diabetic Foot Ulcer
  • Pirfenidone with MODD
  • Ketanserin
  • Guadalajara, Jalisco, Mexico
  • +1 more
Dec 14, 2015

Healthy Trial in Zurich (Placebo, LSD, Ketanserin)

Completed
  • Healthy
  • Placebo
  • +2 more
  • Zurich, Switzerland
    Center for Psychiatric Research, Department of Psychiatry, Psych
Jan 29, 2016

Severe Sepsis, Septic Shock Trial in Leeuwarden (ketanserin)

Completed
  • Severe Sepsis
  • Septic Shock
  • ketanserin
  • Leeuwarden, Netherlands
    Medical Centre Leeuwarden
May 8, 2014

Healthy Trial in Copenhagen (drug, other, dietary supplement)

Completed
  • Healthy
  • Citalopram and Pindolol
  • +2 more
  • Copenhagen, Denmark
    Neurobiology Research Unit, Rigshospitalet
Oct 28, 2015

Complex Regional Pain Syndrome, Type I Trial in Nijmegen (PEPT, CBO standard)

Completed
  • Complex Regional Pain Syndrome, Type I
  • PEPT
  • CBO standard
  • Nijmegen, Netherlands
    Radboud University Medical Center
Jul 23, 2013